Skip to main content
Premium Trial:

Request an Annual Quote

ForteBio Lands $25M in Series C Financing

NEW YORK (GenomeWeb News) – ForteBio has reeled in $25 million in venture capital financing from existing and new investors, the Menlo Park, Calif.-based company said this week.
The Series C financing was led by new investor OrbiMed Advisors, and included investments from another new investor MPM Capital, and existing investors Alloy Ventures, Latterell Venture Partners, the Vertical Group, and Versant Ventures.
OrbiMed Asia’s managing director, Jonathan Wang, and MPM’s managing director, Kazumi Shiosaki, have joined ForteBio’s board of directors.
ForteBio’s president and CEO, Joseph Keegan, said the financing will help the company introduce its products to international markets.
ForteBio markets label-free technologies for real-time analysis of biomolecular interactions, including the Octet QK System and the Octet RED system. The company said it currently has 11 biosensors on the market and that its customer base includes “all of the leading biotechnology companies and 18 of the top 20 pharmaceutical companies.”

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.